VivoSeq
Other

TNBC

3

Pipeline Programs↗

6

Active Trials↗

2

Companies Involved↗

TNBC is an early-stage landscape with 3 programs across 2 companies. The most active players are Avyxa, Summit Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

33/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 2S

Summit Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Ivonescimab

Summit Therapeutics

Carboplatin

Avyxa

Docetaxel

Avyxa

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

11

clinical trials

Recruiting5 · 45%
Withdrawn2 · 18%
Unknown status2 · 18%
Completed1 · 9%
Active, not recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 1·NCT06908928·52 enrolled
Sacituzumab Govitecan In TNBC
Recruiting·MMassachusetts General Hospital·Phase 2·NCT04230109·260 enrolled
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Recruiting·—·Phase 1·NCT06008275·20 enrolled
Saci Nivo Rela for TNBC
Recruiting·YYale University·Phase 1/2·NCT06963905·60 enrolled
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Stage Triple Negative Breast Cancer
Recruiting·CCedars-Sinai Medical Center·Phase 2·NCT07017673·34 enrolled
Ribociclib and Bicalutamide in AR+ TNBC
Active, not recruiting·—·Phase 1/2·NCT03090165·37 enrolled
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
Completed·OOncoSec Medical Incorporated·Phase 1·NCT02531425·10 enrolled
Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
Withdrawn·—·Phase 1·NCT03045393
IL-1 Inhibition in Early TNBC
Withdrawn·UUniversity Health Network, Toronto·Phase 2·NCT06710197
AR-inhibitor Bicalutamide in Treating Patients With TNBC
Unknown status·JJinling Hospital, China·Phase 2·NCT02353988·60 enrolled
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
Unknown status·FFudan University·Phase 2·NCT02607215·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)